Matching-Adjusted Indirect Comparison (Maic) Of Lisocabtagene Maraleucel (Liso-Cel) Vs Axicabtagene Ciloleucel (Axi-Cel) And Tisagenlecleucel In Relapsed/Refractory (R/R) Large B-Cell Lymphoma (Lbcl)

David G. Maloney,John Kuruvilla,Christopher P Fox,Guillaume Cartron,Daniel Li,Jens Hasskarl,Ashley Bonner,Yixie Zhang,Fei Fei Liu

BLOOD（2020）

引用 9|浏览38

暂无评分

摘要

Introduction: Chimeric antigen receptor T cell therapies have shown encouraging, durable responses in patients with R/R LBCL, yet no head-to-head clinical trials comparing options exist to date. We conducted 2 separate pair-wise MAICs to compare treatment effects of liso-cel vs both axi-cel and tisagenlecleucel.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要